American Strategic Investment (NYC) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
20 Nov, 2025Executive summary
Manhattan-focused portfolio with five mixed-use office and retail properties, 80.9% occupancy, and a weighted average remaining lease term of 6.2 years as of Q3 2025, excluding one property in foreclosure.
Top 10 tenants are 69% investment grade (actual and implied), with a 7.1-year average remaining lease term.
Active management included lease renewals, property sales, a consensual foreclosure to eliminate a $99 million debt maturity, and cost-saving initiatives.
Q3 2025 net income was $35.8 million, driven by a $44.3 million non-cash gain from foreclosure, despite lower revenue due to prior asset sales.
Significant liquidity constraints persist, with $10.4 million in cash and restricted cash at quarter-end and ongoing debt service obligations.
Financial highlights
Q3 2025 revenue from tenants was $12.3 million, down from $15.4 million in Q3 2024, mainly due to a prior property sale.
Adjusted EBITDA for Q3 2025 was $1.9 million; cash net operating income was $5.3 million.
Real estate assets at cost: $382.5 million; total debt: $251.0 million.
Operating expenses for Q3 2025: $13.5 million, down from $44.7 million in Q3 2024.
Q3 2025 net income per share: $13.60 (vs. loss of $13.52 in Q3 2024).
Outlook and guidance
Proceeds from property sales, including 123 William Street and 196 Orchard, are intended for higher-yielding investments outside Manhattan to diversify the business.
Operating expenses and capital requirements for the next 12 months are expected to be funded by cash on hand, operations, and other sources.
Continued focus on leasing, tenant renewals, and expense control to enhance operational flexibility.
Management expects cash rent collections to remain at 98% but cannot assure future collections.
Uncertainty remains regarding the ability to raise additional capital or sell assets at expected prices.
Latest events from American Strategic Investment
- $91.9M net loss on $84.7M impairment, $63.5M sale pending, EBITDA and occupancy up.NYC
Q2 20241 Feb 2026 - Q3 net loss rose on impairments; 9 Times Square sale to cut leverage and boost diversification.NYC
Q3 202414 Jan 2026 - Net loss narrowed in Q4 2024 as asset sales improved leverage and a new CEO was appointed.NYC
Q4 202424 Dec 2025 - Annual meeting to vote on director, auditor, and say-on-pay, with all proposals recommended for approval.NYC
Proxy Filing1 Dec 2025 - Virtual annual meeting to vote on director, auditor, and executive pay on May 29, 2025.NYC
Proxy Filing1 Dec 2025 - Revenue and NOI fell, losses widened, but occupancy rose and liquidity risks remain.NYC
Q1 202526 Nov 2025 - Revenue fell, losses narrowed, and liquidity risks rose as asset sales and foreclosures continued.NYC
Q2 202523 Nov 2025